蜗牛
化学
药理学
体内
药物发现
药品
炎症
药物重新定位
奥美拉唑
自噬
重新调整用途
药代动力学
药效学
转录因子
生物活性
细胞生物学
生物化学
结构-活动关系
作者
Zhaolan Zeng,Yang Lu,Mengsha Fang,Xiaopeng Guo,Wenyi Zhong,Geting Xiong,Yu Wang,Fengze Sun,Jinyi Xu,Zhaoqiu Wu,Rong Fu,Jie Liu
标识
DOI:10.1021/acs.jmedchem.6c00152
摘要
The transcription factor Snail plays an important role in the progression of atherosclerosis (AS), actively contributing to plaque formation and instability. Thus, targeting Snail is a promising therapeutic strategy for developing antiatherosclerotic agents possessing both anti-inflammatory and plaque-stabilizing properties. Taking advantage of omeprazole’s Snail-inhibitory activity, as determined through drug repurposing and structure–activity relationships, we identified a novel compound S29, which possesses excellent Snail inhibitory activity, favorable pharmacokinetic properties ( F = 82.3% and T 1/2 = 5.05 h), and enhanced safety profiles. In vivo pharmacodynamic evaluation revealed that S29 remarkably reduced atherosclerotic plaque burden by 56%, as quantified using en face aortas. Mechanistic studies indicated that S29 exerted its therapeutic effects by modulating key factors associated with inflammation and plaque stability, specifically, CCL5, CXCL10, MMP2, MMP9, and α-smooth muscle actin. These findings highlight S29 ’s dual anti-inflammatory and plaque-stabilizing properties, making it a promising candidate for the treatment of AS.
科研通智能强力驱动
Strongly Powered by AbleSci AI